Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

ABSTRACT: Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

PROVIDER: PRJNA638127 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

Project description:Genome-wide patterns of DNA methylation were quantified using the Illumina Infinium HumanMethylation450K BeadChip (“450K array”) in DNA samples isolated from blood for schizophrenia cases, first episode psychosis patients and controls. These samples were profiled as part of a wider study where they were meta-analysed with other cohorts.

2021-04-07 | GSE152027 | GEO

Blood DNA methylation profiles from first episode psychosis patients and controls I

Project description:Genome-wide patterns of DNA methylation were quantified using the Illumina Infinium HumanMethylationEPIC BeadChip (“EPIC array”) in DNA samples isolated from blood for schizophrenia cases, first episode psychosis patients and controls. These samples were profiled as part of a wider study where they were meta-analysed with other cohorts.

2021-04-07 | GSE152026 | GEO

Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

Project description:This study examined the miRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the lncRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the mRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia.

2023-08-30 | GSE228881 | GEO

Expression data from cohort of remitted first-episode schizophrenia patients with less than 5 years of evolution

Project description:To explore the genomic architecture of schizophrenia symptomatology, we analysed blood co-expression modules, i.e. clusters of genes with highly correlated expression, in a cohort of remitted first-episode schizophrenia patients with less than 5 years of evolution, and their association with clinical data, including global functioning, clinical symptomatology and premorbid adjustment.

2022-01-18 | GSE193818 | GEO

Blood DNA methylation profiles from first episode psychosis patients and controls I

Project description:Blood DNA methylation profiles from first episode psychosis patients and controls I

| PRJNA638128 | ENA

First-episode schizophrenia whole blood bulk RNAseq

Project description:Bulk mRNA-sequencing of whole blood samples of first-episode schizophrenia patients and healthy controls

| PRJEB53454 | ENA

Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

Project description:We have previously demonstrated functional and molecular changes in hippocampal subfields in individuals with schizophrenia (SZ) psychosis associated with hippocampal excitability. In this study, we use RNA-seq and assess global transcriptome changes in the hippocampal subfields, DG, CA3, and CA1 from individuals with SZ psychosis and controls to elucidate subfield-relevant molecular changes. We also examine changes in gene expression due to antipsychotic medication in the hippocampal subfields from our SZ ON- and OFF-antipsychotic medication cohort. We identify unique subfield-specific molecular profiles in schizophrenia postmortem samples compared to controls, implicating astrocytes in DG, immune mechanisms in CA3, and synaptic scaling in CA1. We show a unique pattern of subfield-specific effects by antipsychotic medication on gene expression levels with scant overlap of genes differentially expressed by SZ disease effect versus medication effect. These hippocampal subfield changes could provide the basis for previously observed hippocampal SZ pathology and explain the lack of full efficacy of conventional antipsychotic medication on SZ symptomatology. With further characterization, the identified distinct molecular profiles of the DG, CA3, and CA1 in SZ psychosis may serve to identify potential hippocampal-based therapeutic targets.

2020-05-11 | GSE138082 | GEO

Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

Project description:Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

| PRJNA574470 | ENA

Global and targeted metabolomics characterizes antipsychotic medications, amino acid signatures, and platelet-activating factor involvement in first-episode psychosis

Project description:We performed global untargeted metabolomics by LCMS using a Q Exactive Focus mass spectrometer coupled to a Dionex U3000 UHPLC of plasma extract from patients following First Episode Psychosis. Both positive and negative reversed phase injections were performed in triplicate with replicates performed in separate batches. The Biocrates p400 kit was also used to obtain absolute quantification of 400+ metabolites using the vendor kit, column, and data processing tools as provided. The resulting global data was processed with Compound Discoverer 2.1. The resulting output is included within this upload as well as the output from the Biocrates data processing software. Data was integrated using a variety of R scripts as detailed in the associated manuscript.

2021-11-12 | MSV000088371 | MassIVE

Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

Project description:Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

| PRJNA951775 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data